170 related articles for article (PubMed ID: 36351720)
1. Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT).
Zhong J; Brown S; Serra M; Shuttleworth P; Bownes P; Thompson C; Reed R; Reeves K; Dubec M; McHugh D; Eccles C; Chuter R; Tsang YM; Taylor NJ; West C; Buckley D; Scarsbrook A; Choudhury A; Hoskin P; Henry A
BMJ Open; 2022 Nov; 12(11):e068580. PubMed ID: 36351720
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
Valle LF; Lehrer EJ; Markovic D; Elashoff D; Levin-Epstein R; Karnes RJ; Reiter RE; Rettig M; Calais J; Nickols NG; Dess RT; Spratt DE; Steinberg ML; Nguyen PL; Davis BJ; Zaorsky NG; Kishan AU
Eur Urol; 2021 Sep; 80(3):280-292. PubMed ID: 33309278
[TBL] [Abstract][Full Text] [Related]
3. Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review.
Zhong J; Slevin F; Scarsbrook AF; Serra M; Choudhury A; Hoskin PJ; Brown S; Henry AM
Front Oncol; 2021; 11():681448. PubMed ID: 34568012
[TBL] [Abstract][Full Text] [Related]
4. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
[TBL] [Abstract][Full Text] [Related]
5. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
6. Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.
Cozzi S; Finocchi Ghersi S; Bardoscia L; Najafi M; Blandino G; Alì E; Augugliaro M; Vigo F; Ruggieri MP; Cardano R; Giaccherini L; Iori F; Botti A; Trojani V; Ciammella P; Iotti C
Strahlenther Onkol; 2023 Jun; 199(6):554-564. PubMed ID: 36732443
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
[TBL] [Abstract][Full Text] [Related]
8. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
10. F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.
Solanki AA; Yoo RK; Adams W; Davicioni E; Mysz ML; Shea S; Gupta GN; Showalter T; Garant A; Hentz C; Farooq A; Baldea K; Small W; Harkenrider MM
BJU Int; 2024 Feb; 133(2):188-196. PubMed ID: 37562825
[TBL] [Abstract][Full Text] [Related]
11. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
12. Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT).
Jereczek-Fossa BA; Rojas DP; Zerini D; Fodor C; Viola A; Fanetti G; Volpe S; Luraschi R; Bazani A; Rondi E; Cattani F; Vavassori A; Garibaldi C; Alessi S; Pricolo P; Petralia G; Cozzi G; De Cobelli O; Musi G; Orecchia R; Marvaso G; Ciardo D
Br J Radiol; 2019 Feb; 92(1094):20180494. PubMed ID: 30379566
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
14. Is robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected].
Zaorsky NG; Hurwitz MD; Dicker AP; Showalter TN; Den RB
Expert Rev Med Devices; 2015 May; 12(3):317-27. PubMed ID: 25540018
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
16. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
17. Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?
Baty M; Créhange G; Pasquier D; Palard X; Deleuze A; Gnep K; Key S; Beuzit L; Castelli J; de Crevoisier R
Cancer Radiother; 2019 Oct; 23(6-7):541-558. PubMed ID: 31421999
[TBL] [Abstract][Full Text] [Related]
18. The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study.
Pasquier D; Lacornerie T; Supiot S; Pommier P; Quivrin M; Simon JM; Loos G; Meyer E; Calais G; Peiffert D; Vandendorpe B; Aymes E; Leguillette C; Brihoum M; Nenan S; Cormier L; Le Deley MC; Lartigau EF
Eur Urol Oncol; 2023 Aug; 6(4):399-405. PubMed ID: 36754722
[TBL] [Abstract][Full Text] [Related]
19. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332
[TBL] [Abstract][Full Text] [Related]
20. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]